Reported relationships
Latest disclosed role at each company.
| Company | Last reported as | Report date | Published |
|---|---|---|---|
| NEUROONE MEDICAL TECHNOLOGIES CorpNMTC · Entity 7808 | Market Development Director | August 28, 2026 | August 28, 2026 |
Disclosed balances
About these balances
Latest available filing per company, not a reconstructed current portfolio. Matching sequences show the last reported balance with all source rows expandable; grouping alone does not establish account ownership. Do not add unresolved positions together. Filings may omit unchanged positions, and amendments may correct only part of an older disclosure. Jointly reported shares are not necessarily this owner's personal holdings.
NEUROONE MEDICAL TECHNOLOGIES Corp
Report date August 28, 2026 · Filed August 28, 2026
| Security / award | Ownership account | Disclosed shares / units | Disclosure context |
|---|---|---|---|
| Option to Purchase Common StockSEC Table II · derivative / convertible security · Conversion / exercise price $1.77 · Expires 2036-08-27 | Direct | 12,500 |
Reported balance
After 2026-08-28 transaction · row 1
Instrument identity requires review; Table II rows are not merged.
1 source rowRow 1 · 2026-08-28 · Grant · Acquired 12,500 · Balance 12,500 F1: 25% will vest on August 28, 2027, and the remaining 75% will vest in 12 equal quarterly installments. |
Filing footnotes · ownership attribution and instrument terms
F1: 25% will vest on August 28, 2027, and the remaining 75% will vest in 12 equal quarterly installments.
Transaction history
JSON APIPurchases/sales include open-market and private transactions. Plan disclosure applies to the filing; individual rows may differ. “Not disclosed” is not “unplanned.”
The cutoff filters transaction history only. Company summaries and owner relationships show the latest available disclosures. Parser corrections can improve historical records.
| Transaction date | Company | Activity / security | Shares / units | Reported price | Reported value | Details |
|---|---|---|---|---|---|---|
| June 30, 2023 Filed Jul 5, 2023 17:57 UTC | NEUROONE MEDICAL TECHNOLOGIES Corp NMTC · Entity 7808 | Tax withholdingCommon Stock | 90 | $1.20 | $108.00 |
DisclosureSEC source: 0001709738-23-000007 · primary_doc.xml · nonDerivative · entry 1 Christianson Mark · CIK 0001709738 · Business Development Director 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 351,134 Read SEC document |
| May 31, 2023 Filed Jun 1, 2023 20:46 UTC | NEUROONE MEDICAL TECHNOLOGIES Corp NMTC · Entity 7808 | Tax withholdingCommon Stock | 90 | $1.21 | $108.90 |
DisclosureSEC source: 0001709738-23-000006 · primary_doc.xml · nonDerivative · entry 1 Christianson Mark · CIK 0001709738 · Business Development Director 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 351,224 Read SEC document |
| April 30, 2023 Filed May 2, 2023 19:40 UTC | NEUROONE MEDICAL TECHNOLOGIES Corp NMTC · Entity 7808 | Tax withholdingCommon Stock | 90 | $1.54 | $138.60 |
DisclosureSEC source: 0001709738-23-000005 · primary_doc.xml · nonDerivative · entry 1 Christianson Mark · CIK 0001709738 · Business Development Director 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 351,314 Read SEC document |
| April 21, 2023 Filed Apr 25, 2023 19:14 UTC | NEUROONE MEDICAL TECHNOLOGIES Corp NMTC · Entity 7808 | GrantOption to Purchase Common Stock · Derivative | 14,000 | $0.00 Strike: $1.59 | $0.00 |
DisclosureSEC source: 0001709738-23-000004 · primary_doc.xml · derivative · entry 2 Christianson Mark · CIK 0001709738 · Business Development Director 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 14,000 Underlying: Common Stock · 14,000 shares Expires 2033-04-20 F2 · derivative.exercise_date: 25% will vest on April 21, 2024 and the remaining will vest in 12 equal quarterly installments on the last day of each quarter beginning on June 30, 2024. Read SEC document |
| April 21, 2023 Filed Apr 25, 2023 19:14 UTC | NEUROONE MEDICAL TECHNOLOGIES Corp NMTC · Entity 7808 | GrantCommon Stock | 14,000 | $0.00 | $0.00 |
DisclosureSEC source: 0001709738-23-000004 · primary_doc.xml · nonDerivative · entry 1 Christianson Mark · CIK 0001709738 · Business Development Director 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 351,404 F1 · shares: Represents a grant of restricted stock units, which vest as to 50% of the shares on the first anniversary of the grant date, with the remaining shares vesting in equal quarterly installments on the last day of each quarter over the next 8 quarters, subject to continued service on such vesting date. Read SEC document |
| March 31, 2023 Filed Apr 4, 2023 20:22 UTC | NEUROONE MEDICAL TECHNOLOGIES Corp NMTC · Entity 7808 | Tax withholdingCommon Stock | 90 | $1.61 | $144.90 |
DisclosureSEC source: 0001709738-23-000003 · primary_doc.xml · nonDerivative · entry 1 Christianson Mark · CIK 0001709738 · Business Development Director 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 337,404 Read SEC document |
| March 23, 2023 Filed Mar 24, 2023 19:48 UTC | NEUROONE MEDICAL TECHNOLOGIES Corp NMTC · Entity 7808 | SaleCommon Stock | 12,711 | $1.50 | $19,091.92 |
DisclosureSEC source: 0001709738-23-000002 · primary_doc.xml · nonDerivative · entry 3 Christianson Mark · CIK 0001709738 · Business Development Director 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 337,494 F3 · price: The price represents the weighted average price of the multiple transactions reported on this line. The shares were sold at prices ranging from $1.50 to $1.52 per share. Upon request by the SEC staff, the issuer or any securityholder of the issuer, the reporting person will provide full information regarding the number of shares sold at each separate price. Read SEC document |
| March 22, 2023 Filed Mar 24, 2023 19:48 UTC | NEUROONE MEDICAL TECHNOLOGIES Corp NMTC · Entity 7808 | SaleCommon Stock | 11,667 | $1.51 | $17,599.67 |
DisclosureSEC source: 0001709738-23-000002 · primary_doc.xml · nonDerivative · entry 2 Christianson Mark · CIK 0001709738 · Business Development Director 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 350,205 F2 · price: The price represents the weighted average price of the multiple transactions reported on this line. The shares were sold at prices ranging from $1.50 to $1.515 per share. Upon request by the SEC staff, the issuer or any securityholder of the issuer, the reporting person will provide full information regarding the number of shares sold at each separate price. Read SEC document |
| March 21, 2023 Filed Mar 24, 2023 19:48 UTC | NEUROONE MEDICAL TECHNOLOGIES Corp NMTC · Entity 7808 | SaleCommon Stock | 2,122 | $1.60 | $3,405.39 |
DisclosureSEC source: 0001709738-23-000002 · primary_doc.xml · nonDerivative · entry 1 Christianson Mark · CIK 0001709738 · Business Development Director 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 361,872 F1 · price: The price represents the weighted average price of the multiple transactions reported on this line. The shares were sold at prices ranging from $1.60 to $1.61 per share. Upon request by the SEC staff, the issuer or any securityholder of the issuer, the reporting person will provide full information regarding the number of shares sold at each separate price. Read SEC document |
| February 03, 2023 Filed Feb 7, 2023 21:37 UTC | NEUROONE MEDICAL TECHNOLOGIES Corp NMTC · Entity 7808 | Tax withholdingCommon Stock | 2,175 | $1.47 | $3,197.25 |
DisclosureSEC source: 0001709738-23-000001 · primary_doc.xml · nonDerivative · entry 1 Christianson Mark · CIK 0001709738 · Business Development Director 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 363,994 Read SEC document |
| February 03, 2022 Filed Feb 4, 2022 22:44 UTC | NEUROONE MEDICAL TECHNOLOGIES Corp NMTC · Entity 7808 | GrantCommon Stock | 15,000 | $0.00 | $0.00 |
DisclosureSEC source: 0001709738-22-000002 · primary_doc.xml · nonDerivative · entry 1 Christianson Mark · CIK 0001709738 · Business Development Director 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 366,169 F1 · shares: Represents a grant of restricted stock units, which vest as to 50% of the shares on the first anniversary of the grant date, with the remaining shares vesting in equal monthly installments on the last day of each month over the next 24 months, subject to continued service on such vesting date. Read SEC document |
| June 24, 2021 Filed Jun 25, 2021 16:10 UTC | NEUROONE MEDICAL TECHNOLOGIES Corp NMTC · Entity 7808 | SaleCommon Stock | 600 | $6.30 | $3,780.00 |
DisclosureSEC source: 0001709738-21-000001 · primary_doc.xml · nonDerivative · entry 2 Christianson Mark · CIK 0001709738 · Business Development Director 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 1,077,306 Read SEC document |
| June 24, 2021 Filed Feb 4, 2022 22:35 UTC Amendment | NEUROONE MEDICAL TECHNOLOGIES Corp NMTC · Entity 7808 | SaleCommon Stock | 600 | $6.30 | $3,780.00 |
DisclosureSEC source: 0001709738-22-000001 · primary_doc.xml · nonDerivative · entry 2 Christianson Mark · CIK 0001709738 · Business Development Director 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 351,169 F2 · balance_after: This amendment is being filed to correct the number of shares beneficially owned by the reporting person following the reported transaction. The issuer effected a one-for-three reverse stock split of shares of its common stock on March 31, 2021, and the total number of shares held by the reporting person has been corrected to adjust for the split. Read SEC document |
| June 23, 2021 Filed Jun 25, 2021 16:10 UTC | NEUROONE MEDICAL TECHNOLOGIES Corp NMTC · Entity 7808 | SaleCommon Stock | 11,300 | $6.74 | $76,200.42 |
DisclosureSEC source: 0001709738-21-000001 · primary_doc.xml · nonDerivative · entry 1 Christianson Mark · CIK 0001709738 · Business Development Director 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 1,077,906 F1 · price: The price reported in Column 4 is a weighted average price. These shares of the issuer's common stock were sold in multiple transactions at prices ranging from $6.50 to $6.97, inclusive. The reporting person undertakes to provide the issuer, any security holder of the issuer, or the staff of the Securities and Exchange Commission, upon request, full information regarding the number of shares of common stock sold at each separate price within the range set forth in this footnote. Read SEC document |
| June 23, 2021 Filed Feb 4, 2022 22:35 UTC Amendment | NEUROONE MEDICAL TECHNOLOGIES Corp NMTC · Entity 7808 | SaleCommon Stock | 11,300 | $6.74 | $76,200.42 |
DisclosureSEC source: 0001709738-22-000001 · primary_doc.xml · nonDerivative · entry 1 Christianson Mark · CIK 0001709738 · Business Development Director 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 351,769 F1 · price: The price reported in Column 4 is a weighted average price. These shares of the issuer's common stock were sold in multiple transactions at prices ranging from $6.50 to $6.97, inclusive. The reporting person undertakes to provide the issuer, any securityholder of the issuer, or the staff of the Securities and Exchange Commission, upon request, full information regarding the number of shares of common stock sold at each separate price within the range set forth in this footnote. F2 · balance_after: This amendment is being filed to correct the number of shares beneficially owned by the reporting person following the reported transaction. The issuer effected a one-for-three reverse stock split of shares of its common stock on March 31, 2021, and the total number of shares held by the reporting person has been corrected to adjust for the split. Read SEC document |
| June 12, 2020 Filed Jun 16, 2020 18:38 UTC | NEUROONE MEDICAL TECHNOLOGIES Corp NMTC · Entity 7808 | SaleCommon Stock | 334,000 | $0.60 | $200,400.00 |
DisclosureSEC source: 0001596771-20-000052 · primary_doc.xml · nonDerivative · entry 1 Christianson Mark · CIK 0001709738 · VP of Market Development 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 1,089,206 Read SEC document |
| July 20, 2017 Filed Jul 24, 2017 20:02 UTC | NEUROONE MEDICAL TECHNOLOGIES Corp OSOK · Entity 7808 | GrantCommon Stock | 1,423,206 | Not disclosed | Not disclosed |
DisclosureSEC source: 0001596771-17-000063 · primary_doc.xml · nonDerivative · entry 1 Christianson Mark · CIK 0001709738 · VP, Business Dev and Marketing · 10% owner 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 1,423,206 F1 · price: The reporting person acquired the shares of NeuroOne Medical Technologies Corporation ("NMTC") on July 20, 2017, in exchange for shares of the common stock of NeuroOne, Inc. ("NeuroOne"), pursuant to the Agreement and Plan of Merger and Reorganization, dated as of July 20, 2017, between NMTC, OSOK Acquisition Company and NeuroOne, pursuant to which NeuroOne became the wholly-owned subsidiary of NMTC. Per the terms of the Merger Agreement, each share of NeuroOne common stock was converted into the right to receive 17.0103706 shares of NMTC common stock. Read SEC document |
Value uses the disclosed total when available, otherwise shares × reported transaction price. It is not an estimate of exercise cash cost or investment performance.